According to the recent researches on the pathophysiology of heart-failure,β-blockers are no longer considered as the taboo in treating chronic heart failure.But only Bisoprolol,Metoprolol and Carverdilol are used widely in clinic.So we compare the three
According to the recent researches on the pathophysiology of heart-failure,β-blockers are no longer considered as the taboo in treating chronic heart failure.But only Bisoprolol,Metoprolol and Carverdilol are used widely in clinic.So we compare the three
近年来随着慢性心力衰竭病理生理机制研究的不断深入,β受体阻滞剂由过去心衰治疗的禁忌证转变为适应证,目前循证医学结果显示只有比索洛尔、美托洛尔和卡维地洛三种β-受体阻滞剂适用于慢性心力衰竭的临床治疗,本文就这三者从临床药理学和循证医学角度作一比较,结果显示:美托洛尔和比索洛尔临床疗效相似,卡维地洛较前两者更佳。